Clinical Trials Browser

OTHER × Paraproteinemias × daratumumab × Clear all

NCT03236428 2025-03-05

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Phase 2 Active not recruiting

Smoldering Multiple Myeloma, Paraproteinemias

NCT05581875 2022-10-17

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Phase 1/2 Not yet recruiting

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell